• Transactions
  • News
  • Events
  • Contact
  • SVB.com
  • Skip to primary navigation
  • Skip to main content
  • Skip to footer

SVB Securities

Helping our clients move healthcare and technology forward

  • Firm
    • About
    • Careers
    • News
  • Expertise
    • Healthcare Investment Banking
    • Tech Investment Banking
    • Equity Capital Markets
    • Equity Research
    • Institutional Equities
    • Corporate Access
    • SVB MEDACorp
  • Sectors
    • Healthcare
    • Biopharma
    • Digital Health & HealthTech
    • Healthcare Services
    • Medical Devices
    • Tools & Diagnostics
    • Technology
    • Consumer Internet, Commerce Enablement & Marketing Software
    • Digital Infrastructure and Tech-Enabled Services
    • Education Technology
    • Enterprise Software
    • Industrial Technology
    • FinTech
  • Log in
  • Transactions
  • News
  • Events
  • Contact
  • SVB.com

Research Archive

April 2022

Biopharma / TIGIT Clinical Updates at AACR Incrementally Positive

View research note
March 2022

Healthcare Providers and Managed Care / Home Health: More Downside Risk to Ests Against an Improving Operating Backdrop

View research note
February 2022

Biopharma / Key Takeaways from GHC Panel on Bispecifics vs. Cell Therapy in NHL and MM

View research note
January 2022

Healthcare / Liquid Biopsy Nearing the Finish Line in CRC Screening Race

View research note
December 2021

Biopharma — Flash / Big Biopharma Will Have $500Bn in Gross Cash to Deploy YE22 – Get Set for M&A

View research note
November 2021

Biopharma — Flash / Not to be Alarmist but Omicron is Alarming; Good for PFE & Other Incumbents

View research note
October 2021

Healthcare / Over or Underreaction? SVBL Analysts on Molnupiravir and Its Impact

View research note
September 2021

Biopharma / Immuno-Oncology Round-up from ESMO 2021

View research note
August 2021

FT516 & FT596 in NHL Give 4 Strong, 3 Weak, and 5 Uncertain Signals

View research note
July 2021

VRTX / Seen This Movie Before? Another Biopharma Multiple Compression Saga, PT to $170 / Underperform

View research note
June 2021

NTRA / Making Sense of the Signatera ADLT; Increasing Estimates, PT to $160 / Outperform

View research note
May 2021

Life Science Tools and Diagnostics / Comparing Performance of Leading MRD Liquid Biopsy Tests as Early Data Emerges

View research note
April 2021

Biopharma / Three DC Risks That Could Keep Biopharma Multiples Depressed All Year

View research note
March 2021

Life Science Tools and Diagnostics Volatility Creates Opportunities: Highlighting Winners Among the Crash Landing

View research note
February 2021

Biopharma / 2021 MEDACorp IBD Physician Survey Shows Novel Orals Set to Expand Market

View research note
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to Next Page »

Partner With Us

We deliver a complete suite of capital market and advisory solutions to help our clients define and achieve their strategic, capital market, and investment objectives.

Contact Us

Footer

Firm

  • About
  • Careers
  • Events
  • Terms of Use
  • Member FINRA/SIPC, www.finra.org
  • Privacy Notice
  • Notice to California residents
  • Important Disclosures

Expertise

  • Healthcare Investment Banking
  • Tech Investment Banking
  • Capital Markets
  • M&A Advisory
  • Institutional Equities
  • Equity Research
  • SVB MEDACorp

Sectors

  • Biopharma
  • Medical Devices
  • Tools & Diagnostics
  • Healthcare Services
  • Consumer Internet, Commerce Enablement & Marketing Software
  • Digital Infrastructure and Tech-Enabled Services
  • Education Technology
  • Enterprise Software
  • Industrial Technology
  • FinTech

Other

  • News
  • Transactions
  • Contact
  • SVB.com
An SVB Company